[F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model.
[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is a non-invasive imaging technique which has recently been validated for the assessment of therapy response in patients with aggressive non-Hodgkin's lymphoma. Our objective was to determine its value for the evaluation of immunotherapy efficacy in immunocompetent Balb/c mice injected with the A20 syngeneic B lymphoma cell line. The high level of in vitro FDG uptake by A20 cells validated the model for further imaging studies. When injected intravenously, the tumour developed as nodular lesions mostly in liver and spleen, thus mimicking the natural course of an aggressive human lymphoma. FDG-PET provided three-dimensional images of tumour extension including non-palpable lesions, in good correlation with ex vivo macroscopic examination. When mice were pre-immunized with an A20 cell lysate in adjuvant before tumour challenge, their significantly longer survival, compared to control mice, were associated with a lower incidence of lymphoma visualized by PET at different time points. Estimation of tumour growth and metabolism using the calculated tumour volumes and maximum standardized uptake values, respectively, also demonstrated delayed lymphoma development and lower activity in the vaccinated mice. Thus, FDG-PET is a sensitive tool relevant for early detection and follow-up of internal tumours, allowing discrimination between treated and non-treated small animal cohorts without invasive intervention.
Chaise
Coralie
C
INSERM, U617, Créteil, 94000, France.
Itti
Emmanuel
E
Petegnief
Yolande
Y
Wirquin
Evelyne
E
Copie-Bergman
Christiane
C
Farcet
Jean-Pierre
JP
Delfau-Larue
Marie-Hélène
MH
Meignan
Michel
M
Talbot
Jean-Noël
JN
Molinier-Frenkel
Valérie
V
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D045744:Cell Line, Tumor / Q000378:metabolism; D042241:Early Diagnosis; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D021621:Imaging, Three-Dimensional; D007121:Immunocompetence; D016233:Immunotherapy, Active; D007275:Injections, Intravenous; D008099:Liver / Q000000981:diagnostic imaging / Q000473:pathology; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D012515:Mast-Cell Sarcoma / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013154:Spleen / Q000000981:diagnostic imaging / Q000473:pathology; D013623:Tail / Q000098:blood supply
D019496:Cancer Vaccines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18